{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T01:36:38Z","timestamp":1775266598117,"version":"3.50.1"},"reference-count":92,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T00:00:00Z","timestamp":1495670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["14-25-00160"],"award-info":[{"award-number":["14-25-00160"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cytokine neutralization is successfully used for treatment of various autoimmune diseases and chronic inflammatory conditions. The complex biology of the two well-characterized proinflammatory cytokines TNF and IL-6 implicates unavoidable consequences when it comes to their global blockade. Because systemic cytokine ablation may result in unwanted side effects, efforts have been made to develop more specific cytokine inhibitors, which would spare the protective immunoregulatory functions of a given cytokine. In this article, we review current research and summarize new strategies for improved anti-TNF and anti-IL-6 biologics, which specifically target only selected parts of the signaling cascades mediated by these ligands.<\/jats:p>","DOI":"10.1189\/jlb.3ma0117-025r","type":"journal-article","created":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T00:40:23Z","timestamp":1495759223000},"page":"783-790","source":"Crossref","is-referenced-by-count":18,"title":["Can we design a better anti-cytokine therapy?"],"prefix":"10.1093","volume":"102","author":[{"given":"Marina S","family":"Drutskaya","sequence":"first","affiliation":[{"name":"Engelhardt Institute of Molecular Biology, Russian Academy of Sciences , Moscow, Russia"},{"name":"Lomonosov Moscow State University , Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grigory A","family":"Efimov","sequence":"additional","affiliation":[{"name":"Engelhardt Institute of Molecular Biology, Russian Academy of Sciences , Moscow, Russia"},{"name":"National Research Center for Hematology , Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrei A","family":"Kruglov","sequence":"additional","affiliation":[{"name":"Engelhardt Institute of Molecular Biology, Russian Academy of Sciences , Moscow, Russia"},{"name":"Lomonosov Moscow State University , Moscow, Russia"},{"name":"German Rheumatism Research Center (DRFZ) , Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergei A","family":"Nedospasov","sequence":"additional","affiliation":[{"name":"Engelhardt Institute of Molecular Biology, Russian Academy of Sciences , Moscow, Russia"},{"name":"Lomonosov Moscow State University , Moscow, Russia"},{"name":"German Rheumatism Research Center (DRFZ) , Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,5,25]]},"reference":[{"key":"2023013012233731700_B1","doi-asserted-by":"crossref","first-page":"791","DOI":"10.4049\/jimmunol.1090051","article-title":"Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us?","volume":"185","author":"Feldmann","year":"2010","journal-title":"J. Immunol."},{"key":"2023013012233731700_B2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol. Ther."},{"key":"2023013012233731700_B3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/intimm\/dxu102","article-title":"Anti-TNF therapy: past, present and future","volume":"27","author":"Monaco","year":"2015","journal-title":"Int. Immunol."},{"key":"2023013012233731700_B4","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/qjmed\/hcq152","article-title":"TNF-alpha antagonists beyond approved indications: stories of success and prospects for the future","volume":"103","author":"Karampetsou","year":"2010","journal-title":"QJM"},{"key":"2023013012233731700_B5","doi-asserted-by":"crossref","first-page":"14805","DOI":"10.1038\/ncomms14805","article-title":"Constitutive smooth muscle tumour necrosis factor regulates microvascular myogenic responsiveness and systemic blood pressure","volume":"8","author":"Kroetsch","year":"2017","journal-title":"Nat. Commun."},{"key":"2023013012233731700_B6","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1126\/science.274.5291.1379","article-title":"Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice","volume":"274","author":"Cressman","year":"1996","journal-title":"Science"},{"key":"2023013012233731700_B7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ccr.2009.01.001","article-title":"IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer","volume":"15","author":"Grivennikov","year":"2009","journal-title":"Cancer Cell"},{"key":"2023013012233731700_B8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.celrep.2017.03.043","article-title":"IL-6 improves energy and glucose homeostasis in obesity via enhanced central IL-6 trans-signaling","volume":"19","author":"Timper","year":"2017","journal-title":"Cell Rep."},{"key":"2023013012233731700_B9","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"2023013012233731700_B10","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1136\/annrheumdis-2013-205002","article-title":"IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab","volume":"73","author":"Tanaka","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"2023013012233731700_B11","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.2119\/molmed.2014.00232","article-title":"An expanding role for interleukin-1 blockade from gout to cancer","volume":"20","author":"Dinarello","year":"2014","journal-title":"Mol. Med."},{"key":"2023013012233731700_B12","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s12272-015-0569-8","article-title":"IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future","volume":"38","author":"Kim","year":"2015","journal-title":"Arch. Pharm. Res."},{"key":"2023013012233731700_B13","doi-asserted-by":"crossref","first-page":"216","DOI":"10.4161\/mabs.1.3.8593","article-title":"Ustekinumab","volume":"1","author":"Cingoz","year":"2009","journal-title":"MAbs"},{"key":"2023013012233731700_B14","doi-asserted-by":"crossref","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"2023013012233731700_B15","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.4049\/jimmunol.164.12.6193","article-title":"Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages","volume":"164","author":"Eissner","year":"2000","journal-title":"J. Immunol."},{"key":"2023013012233731700_B16","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1189\/jlb.0703343","article-title":"LPS resistance in monocytic cells caused by reverse signaling through transmembrane TNF (mTNF) is mediated by the MAPK\/ERK pathway","volume":"75","author":"Kirchner","year":"2004","journal-title":"J. Leukoc. Biol."},{"key":"2023013012233731700_B17","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.4049\/jimmunol.1501573","article-title":"Transmembrane TNF-\u03b1 reverse signaling inhibits lipopolysaccharide-induced proinflammatory cytokine formation in macrophages by inducing TGF-\u03b2: therapeutic implications","volume":"196","author":"Pallai","year":"2016","journal-title":"J. Immunol."},{"key":"2023013012233731700_B18","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.phrs.2016.11.025","article-title":"Transmembrane TNF-alpha reverse signaling leading to TGF-beta production is selectively activated by TNF targeting molecules: therapeutic implications","volume":"115","author":"Szondy","year":"2017","journal-title":"Pharmacol. Res."},{"key":"2023013012233731700_B19","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/385729a0","article-title":"A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells","volume":"385","author":"Black","year":"1997","journal-title":"Nature"},{"key":"2023013012233731700_B20","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/385733a0","article-title":"Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha (published correction in Nature 1997;386;738)","volume":"385","author":"Moss","year":"1997","journal-title":"Nature"},{"key":"2023013012233731700_B21","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.4049\/jimmunol.179.5.2686","article-title":"Cutting edge: TNF-alpha-converting enzyme (TACE\/ADAM17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock","volume":"179","author":"Horiuchi","year":"2007","journal-title":"J. Immunol."},{"key":"2023013012233731700_B22","first-page":"93","article-title":"Distinct and nonredundant in vivo functions of TNF produced by t cells and macrophages\/neutrophils: protective and deleterious effects","volume":"22","author":"Grivennikov","year":"2005","journal-title":"Immunity"},{"key":"2023013012233731700_B23","doi-asserted-by":"crossref","first-page":"5660","DOI":"10.4049\/jimmunol.1100663","article-title":"Pathogenic and protective functions of TNF in neuroinflammation are defined by its expression in T lymphocytes and myeloid cells","volume":"187","author":"Kruglov","year":"2011","journal-title":"J. Immunol."},{"key":"2023013012233731700_B24","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood-2009-10-249177","article-title":"Cellular source and molecular form of TNF specify its distinct functions in organization of secondary lymphoid organs","volume":"116","author":"Tumanov","year":"2010","journal-title":"Blood"},{"key":"2023013012233731700_B25","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm.3869","article-title":"Nilotinib reduces muscle fibrosis in chronic muscle injury by promoting TNF-mediated apoptosis of fibro\/adipogenic progenitors","volume":"21","author":"Lemos","year":"2015","journal-title":"Nat. Med."},{"key":"2023013012233731700_B26","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/ni.3215","article-title":"Inflammation-induced formation of fat-associated lymphoid clusters","volume":"16","author":"B\u00e9n\u00e9zech","year":"2015","journal-title":"Nat. Immunol."},{"key":"2023013012233731700_B27","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.2337\/db15-1450","article-title":"Tumor necrosis factor\/sphingosine-1-phosphate signaling augments resistance artery myogenic tone in diabetes","volume":"65","author":"Sauv\u00e9","year":"2016","journal-title":"Diabetes"},{"key":"2023013012233731700_B28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1084\/jem.189.1.159","article-title":"Mature follicular dendritic cell networks depend on expression of lymphotoxin beta receptor by radioresistant stromal cells and of lymphotoxin beta and tumor necrosis factor by B cells","volume":"189","author":"Endres","year":"1999","journal-title":"J. Exp. Med."},{"key":"2023013012233731700_B29","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1084\/jem.189.2.403","article-title":"Lymphotoxin alpha\/beta and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen","volume":"189","author":"Ngo","year":"1999","journal-title":"J. Exp. Med."},{"key":"2023013012233731700_B30","doi-asserted-by":"crossref","first-page":"11294","DOI":"10.1073\/pnas.92.24.11294","article-title":"Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha","volume":"92","author":"Probert","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2023013012233731700_B31","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1084\/jem.190.5.629","article-title":"The requirement of membrane lymphotoxin for the presence of dendritic cells in lymphoid tissues","volume":"190","author":"Wu","year":"1999","journal-title":"J. Exp. Med."},{"key":"2023013012233731700_B32","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/jlb.59.4.518","article-title":"Dissection of the pathologies induced by transmembrane and wild-type tumor necrosis factor in transgenic mice","volume":"59","author":"Probert","year":"1996","journal-title":"J. Leukoc. Biol."},{"key":"2023013012233731700_B33","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1084\/jem.184.4.1397","article-title":"Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response","volume":"184","author":"Pasparakis","year":"1996","journal-title":"J. Exp. Med."},{"key":"2023013012233731700_B34","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/0092-8674(95)90192-2","article-title":"The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor","volume":"83","author":"Grell","year":"1995","journal-title":"Cell"},{"key":"2023013012233731700_B35","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.neuroscience.2015.06.038","article-title":"TNF and its receptors in the CNS: the essential, the desirable and the deleterious effects","volume":"302","author":"Probert","year":"2015","journal-title":"Neuroscience"},{"key":"2023013012233731700_B36","doi-asserted-by":"crossref","first-page":"12304","DOI":"10.1073\/pnas.1605195113","article-title":"Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration","volume":"113","author":"Dong","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2023013012233731700_B37","doi-asserted-by":"crossref","first-page":"32834","DOI":"10.1038\/srep32834","article-title":"TNFR2 expression by CD4 effector T cells is required to induce full-fledged experimental colitis","volume":"6","author":"Chen","year":"2016","journal-title":"Sci. Rep."},{"key":"2023013012233731700_B38","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.4049\/jimmunol.1202659","article-title":"TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory T cell phenotype in the inflammatory environment","volume":"190","author":"Chen","year":"2013","journal-title":"J. Immunol."},{"key":"2023013012233731700_B39","doi-asserted-by":"crossref","first-page":"eaaf8608","DOI":"10.1126\/scisignal.aaf8608","article-title":"Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs","volume":"10","author":"Torrey","year":"2017","journal-title":"Sci. Signal."},{"key":"2023013012233731700_B40","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/iid3.19","article-title":"Myeloid suppressor cells require membrane TNFR2 expression for suppressive activity","volume":"2","author":"Polz","year":"2014","journal-title":"Immun. Inflamm. Dis."},{"key":"2023013012233731700_B41","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1172\/JCI64115","article-title":"TNF signaling drives myeloid-derived suppressor cell accumulation","volume":"122","author":"Zhao","year":"2012","journal-title":"J. Clin. Invest."},{"key":"2023013012233731700_B42","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrrheum.2015.169","article-title":"TNF biology, pathogenic mechanisms and emerging therapeutic strategies","volume":"12","author":"Kalliolias","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"2023013012233731700_B43","doi-asserted-by":"crossref","first-page":"639","DOI":"10.4161\/mabs.2.6.13583","article-title":"ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody","volume":"2","author":"Zettlitz","year":"2010","journal-title":"MAbs"},{"key":"2023013012233731700_B44","doi-asserted-by":"crossref","first-page":"e72156","DOI":"10.1371\/journal.pone.0072156","article-title":"Antagonistic TNF receptor one-specific antibody (ATROSAB): receptor binding and in vitro bioactivity","volume":"8","author":"Richter","year":"2013","journal-title":"PLoS One"},{"key":"2023013012233731700_B45","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1074\/jbc.M114.617787","article-title":"Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1","volume":"290","author":"Steeland","year":"2015","journal-title":"J. Biol. Chem."},{"key":"2023013012233731700_B46","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1002\/art.38055","article-title":"Selective blockade of tumor necrosis factor receptor I inhibits proinflammatory cytokine and chemokine production in human rheumatoid arthritis synovial membrane cell cultures","volume":"65","author":"Schmidt","year":"2013","journal-title":"Arthritis Rheum."},{"key":"2023013012233731700_B47","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/art.38755","article-title":"Selective tumor necrosis factor receptor I blockade is antiinflammatory and reveals immunoregulatory role of tumor necrosis factor receptor II in collagen-induced arthritis","volume":"66","author":"McCann","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"2023013012233731700_B48","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3389\/fimmu.2016.00147","article-title":"TNF neutralization results in the delay of transplantable tumor growth and reduced MDSC accumulation","volume":"7","author":"Atretkhany","year":"2016","journal-title":"Front. Immunol."},{"key":"2023013012233731700_B49","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1126\/science.1243364","article-title":"Nonredundant function of soluble LT\u03b13 produced by innate lymphoid cells in intestinal homeostasis","volume":"342","author":"Kruglov","year":"2013","journal-title":"Science"},{"key":"2023013012233731700_B50","doi-asserted-by":"crossref","first-page":"e27621","DOI":"10.1371\/journal.pone.0027621","article-title":"A TNF receptor 2 selective agonist rescues human neurons from oxidative stress-induced cell death","volume":"6","author":"Fischer","year":"2011","journal-title":"PLoS One"},{"key":"2023013012233731700_B51","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1038\/cti.2015.43","article-title":"Treg activation defect in type 1 diabetes: correction with TNFR2 agonism","volume":"5","author":"Okubo","year":"2016","journal-title":"Clin. Transl. Immunology"},{"key":"2023013012233731700_B52","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1126\/science.1081297","article-title":"Inactivation of TNF signaling by rationally designed dominant-negative TNF variants","volume":"301","author":"Steed","year":"2003","journal-title":"Science"},{"key":"2023013012233731700_B53","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1165\/rcmb.2010-0512OC","article-title":"Allergic lung inflammation is mediated by soluble tumor necrosis factor (TNF) and attenuated by dominant-negative TNF biologics","volume":"45","author":"Maillet","year":"2011","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2023013012233731700_B54","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.4049\/jimmunol.179.3.1872","article-title":"Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection","volume":"179","author":"Zalevsky","year":"2007","journal-title":"J. Immunol."},{"key":"2023013012233731700_B55","doi-asserted-by":"crossref","first-page":"9365","DOI":"10.1523\/JNEUROSCI.1504-06.2006","article-title":"Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease","volume":"26","author":"McCoy","year":"2006","journal-title":"J. Neurosci."},{"key":"2023013012233731700_B56","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.nbd.2009.01.006","article-title":"Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology","volume":"34","author":"McAlpine","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"2023013012233731700_B57","doi-asserted-by":"crossref","first-page":"e38170","DOI":"10.1371\/journal.pone.0038170","article-title":"Inhibition of soluble tumor necrosis factor ameliorates synaptic alterations and Ca2+ dysregulation in aged rats","volume":"7","author":"Sama","year":"2012","journal-title":"PLoS One"},{"key":"2023013012233731700_B58","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1074\/jbc.M707933200","article-title":"Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist","volume":"283","author":"Shibata","year":"2008","journal-title":"J. Biol. Chem."},{"key":"2023013012233731700_B59","doi-asserted-by":"crossref","first-page":"36","DOI":"10.5551\/jat.9746","article-title":"Novel TNF-\u03b1 receptor 1 antagonist treatment attenuates arterial inflammation and intimal hyperplasia in mice","volume":"19","author":"Kitagaki","year":"2012","journal-title":"J. Atheroscler. Thromb."},{"key":"2023013012233731700_B60","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.1073\/pnas.84.20.7251","article-title":"Interferon beta 2\/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells","volume":"84","author":"Gauldie","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2023013012233731700_B61","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/intimm\/dxh396","article-title":"Differential expression of CD126 and CD130 mediates different STAT-3 phosphorylation in CD4+CD25- and CD25high regulatory T cells","volume":"18","author":"Oberg","year":"2006","journal-title":"Int. Immunol."},{"key":"2023013012233731700_B62","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cytogfr.2015.07.004","article-title":"Interleukin-6: biology, signaling and strategies of blockade","volume":"26","author":"Schaper","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"2023013012233731700_B63","doi-asserted-by":"crossref","first-page":"16186","DOI":"10.1074\/jbc.M116.718551","article-title":"Different soluble forms of the interleukin-6 family signal transducer gp130 fine-tune the blockade of interleukin-6 trans-signaling","volume":"291","author":"Wolf","year":"2016","journal-title":"J. Biol. Chem."},{"key":"2023013012233731700_B64","doi-asserted-by":"crossref","first-page":"8222","DOI":"10.1073\/pnas.95.14.8222","article-title":"Interleukin 6 plays a key role in the development of antigen-induced arthritis","volume":"95","author":"Ohshima","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2023013012233731700_B65","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ni.3632","article-title":"Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells","volume":"18","author":"Heink","year":"2017","journal-title":"Nat. Immunol."},{"key":"2023013012233731700_B66","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.4049\/jimmunol.0900242","article-title":"Site-specific production of IL-6 in the central nervous system retargets and enhances the inflammatory response in experimental autoimmune encephalomyelitis","volume":"183","author":"Quintana","year":"2009","journal-title":"J. Immunol."},{"key":"2023013012233731700_B67","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bbi.2012.10.011","article-title":"Astrocyte-specific deficiency of interleukin-6 and its receptor reveal specific roles in survival, body weight and behavior","volume":"27","author":"Quintana","year":"2013","journal-title":"Brain Behav. Immun."},{"key":"2023013012233731700_B68","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.cell.2013.09.031","article-title":"Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling","volume":"155","author":"He","year":"2013","journal-title":"Cell"},{"key":"2023013012233731700_B69","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1159\/000341698","article-title":"Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease","volume":"30","author":"Chalaris","year":"2012","journal-title":"Dig. Dis."},{"key":"2023013012233731700_B70","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.coi.2015.02.008","article-title":"The IL-6\/gp130\/STAT3 signaling axis: recent advances towards specific inhibition","volume":"34","author":"Garbers","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"2023013012233731700_B71","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/art.34477","article-title":"Brief report: inhibition of interleukin-6 function corrects Th17\/Treg cell imbalance in patients with rheumatoid arthritis","volume":"64","author":"Samson","year":"2012","journal-title":"Arthritis Rheum."},{"key":"2023013012233731700_B72","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/CCM.0b013e318211ff56","article-title":"Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model","volume":"39","author":"Barkhausen","year":"2011","journal-title":"Crit. Care Med."},{"key":"2023013012233731700_B73","doi-asserted-by":"crossref","first-page":"613","DOI":"10.4049\/jimmunol.182.1.613","article-title":"Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis","volume":"182","author":"Nowell","year":"2009","journal-title":"J. Immunol."},{"key":"2023013012233731700_B74","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/75068","article-title":"Blockade of interleukin 6 trans signaling suppresses T cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo","volume":"6","author":"Atreya","year":"2000","journal-title":"Nat. Med."},{"key":"2023013012233731700_B75","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.immuni.2016.04.003","article-title":"CD5 binds to interleukin-6 and induces a feed-forward loop with the transcription factor STAT3 in B cells to promote cancer","volume":"44","author":"Zhang","year":"2016","journal-title":"Immunity"},{"key":"2023013012233731700_B76","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/art.27346","article-title":"Human single-chain variable fragment that specifically targets arthritic cartilage","volume":"62","author":"Hughes","year":"2010","journal-title":"Arthritis Rheum."},{"key":"2023013012233731700_B77","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.24331","article-title":"Membrane type 1 matrix metalloproteinase is a crucial promoter of synovial invasion in human rheumatoid arthritis","volume":"60","author":"Miller","year":"2009","journal-title":"Arthritis Rheum."},{"key":"2023013012233731700_B78","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/art.39414","article-title":"Selective inhibition of membrane type 1 matrix metalloproteinase abrogates progression of experimental inflammatory arthritis: synergy with tumor necrosis factor blockade","volume":"68","author":"Kaneko","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"2023013012233731700_B79","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1126\/science.1137306","article-title":"Cadherin-11 in synovial lining formation and pathology in arthritis","volume":"315","author":"Lee","year":"2007","journal-title":"Science"},{"key":"2023013012233731700_B80","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nrrheum.2016.91","article-title":"Macrophage heterogeneity in the context of rheumatoid arthritis","volume":"12","author":"Udalova","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"2023013012233731700_B81","first-page":"35","article-title":"Why does tumor necrosis factor targeted therapy reactivate tuberculosis?","volume":"74","author":"Ehlers","year":"2005","journal-title":"J. Rheumatol. Suppl."},{"key":"2023013012233731700_B82","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1086\/421494","article-title":"Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor","volume":"39","author":"Mohan","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"2023013012233731700_B83","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1038\/srep01809","article-title":"Prominent role for T cell-derived tumour necrosis factor for sustained control of Mycobacterium tuberculosis infection","volume":"3","author":"Allie","year":"2013","journal-title":"Sci. Rep."},{"key":"2023013012233731700_B84","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1073\/pnas.1520175113","article-title":"Cell-type-restricted anti-cytokine therapy: TNF inhibition from one pathogenic source","volume":"113","author":"Efimov","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2023013012233731700_B85","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nrrheum.2016.38","article-title":"Therapy: cell-type-specific approach to TNF inhibition","volume":"12","author":"Onuora","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"2023013012233731700_B86","doi-asserted-by":"crossref","first-page":"7346","DOI":"10.1074\/jbc.M007734200","article-title":"Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs","volume":"276","author":"Els Conrath","year":"2001","journal-title":"J. Biol. Chem."},{"key":"2023013012233731700_B87","first-page":"1382","article-title":"Molecular analysis of heavy chain-only antibodies of Camelus bactrianus","volume":"79","author":"Tillib","year":"2014","journal-title":"Biochemistry"},{"key":"2023013012233731700_B88","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1128\/IAI.00743-15","article-title":"Control of mycobacterial infections in mice expressing human tumor necrosis factor (TNF) but not mouse TNF","volume":"83","author":"Olleros","year":"2015","journal-title":"Infect. Immun."},{"key":"2023013012233731700_B89","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/19420862.2015.1093266","article-title":"Discovery and characterization of COVA322, a clinical-stage bispecific TNF\/IL-17A inhibitor for the treatment of inflammatory diseases","volume":"8","author":"Silacci","year":"2016","journal-title":"MAbs"},{"key":"2023013012233731700_B90","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/19420862.2016.1172163","article-title":"An optimized antibody-single-chain TRAIL fusion protein for cancer therapy","volume":"8","author":"Siegemund","year":"2016","journal-title":"MAbs"},{"key":"2023013012233731700_B91","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","article-title":"Bispecific T cell engaging antibodies for cancer therapy","volume":"69","author":"Baeuerle","year":"2009","journal-title":"Cancer Res."},{"key":"2023013012233731700_B92","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.190.10.1479","article-title":"Nonlymphocyte-derived tumor necrosis factor is required for induction of colitis in recombination activating gene (RAG)2(\u2013\/\u2013) mice upon transfer of CD4(+)CD45RB(hi) T cells","volume":"190","author":"Corazza","year":"1999","journal-title":"J. Exp. Med."}],"container-title":["Journal of Leukocyte Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1189\/jlb.3MA0117-025R","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1189\/jlb.3MA0117-025R","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jleukbio\/article-pdf\/102\/3\/783\/48170373\/jlb0783.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jleukbio\/article-pdf\/102\/3\/783\/48170373\/jlb0783.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T13:34:21Z","timestamp":1677504861000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jleukbio\/article\/102\/3\/783\/6935475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,25]]},"references-count":92,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,5,25]]},"published-print":{"date-parts":[[2017,5,25]]}},"URL":"https:\/\/doi.org\/10.1189\/jlb.3ma0117-025r","relation":{},"ISSN":["0741-5400","1938-3673"],"issn-type":[{"value":"0741-5400","type":"print"},{"value":"1938-3673","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,9]]},"published":{"date-parts":[[2017,5,25]]}}}